Development and validation of a multi-parameter nomogram for predicting prostate cancer: a retrospective analysis from Handan Central Hospital in China

Development and validation of a multi-parameter nomogram for predicting prostate cancer: a retrospective analysis from Handan Central Hospital in China

Background To explore the possible predicting factors related to prostate cancer and develop a validated nomogram for predicting the probability of patients with prostate cancer. Method Clinical data of 697 patients who underwent prostate biopsy in Handan Central Hospital from January 2014 to Januar...

Full description

Bibliographic Details
Main Authors:	Libin Nan, Kai Guo, Mingmin Li, Qi Wu, Shaojun Huo
Format:	Article
Language:	English
Published:	PeerJ Inc. 2022-03-01
Series:	PeerJ
Subjects:	Prostatic neoplasms Prostate-specific antigen Nomograms
Online Access:	https://peerj.com/articles/12912.pdf

Similar Items

Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy‐naive men based on multi‐institutional analysis
by: Qingyu Ge, et al.
Published: (2023-12-01)

Retrospective study comparing six - and twelve-core prostate biopsy in detection of prostate cancer
by: Motoi Tobiume, et al.
Published: (2008-02-01)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Metastatic prostate cancer in the modern era of PSA screening
by: Philip A. Fontenot Jr, et al.

Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases
by: Edmund Chiong, et al.
Published: (2005-07-01)

Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?
by: Jun Seok Kim, et al.
Published: (2015-04-01)

Development of novel nomograms for predicting prostate cancer in biopsy-naive patients with PSA < 10 ng/ml and PI-RADS ≤ 3 lesions
by: Jia-gui Chai, et al.
Published: (2025-01-01)

The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen
by: Hee Ju Cho, et al.
Published: (2014-12-01)

How to avoid prostate biopsy in men with Prostate Image-Reporting and Data System 3 lesion? Development and external validation of new biopsy indication using prostate health index density
by: Jae Yeon Kim, et al.
Published: (2023-09-01)

BioPrev-C – development and validation of a contemporary prostate cancer risk calculator
by: Thomas Hermanns, et al.
Published: (2024-02-01)

Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis
by: Yan Jin, et al.
Published: (2022-05-01)

Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy
by: Yong Hyun Park, et al.
Published: (2014-03-01)

Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination
by: Peter Ka-Fung Chiu, et al.
Published: (2016-09-01)

CUT-OFF VALUES OF PROSTATE SPECIFIC ANTIGEN DENSITY– AN EFFECTIVE SCREENING MARKER BEFORE PROSTATE BIOPSY
by: Zujaja Hina Haroon, et al.
Published: (2022-03-01)

Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy
by: Ernani L. Rhoden, et al.
Published: (2003-04-01)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
by: I. Vukovic, et al.

Nadir prostate-specific antigen as a prognostic factor of 10-year cancer-specific survival of prostate cancer patients with bone metastases
by: Chi-Feng Hung, et al.
Published: (2022-01-01)

Prevalence of prostate adenocarcinoma according to race in an university hospital
by: Milton S Barros, et al.
Published: (2003-08-01)

Racial influence on the prevalence of prostate carcinoma in Brazilian volunteers
by: Edson L Paschoalin, et al.
Published: (2003-08-01)

Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5–10 ng/mL
by: Joongwon Choi, et al.
Published: (2020-11-01)

Correlation between prostate-specific antigen and histopathological difference of prostate carcinoma
by: Živković Slađana
Published: (2004-01-01)

The COVID-19 pandemic's impact on prostate cancer screening and diagnosis in Korea
by: Byeong Jin Kang, et al.
Published: (2023-09-01)

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
by: Tae Hwan Kim, et al.
Published: (2023-11-01)

Unilateral testicular metastasis of prostate cancer
by: Ravi Hari Phulware, et al.
Published: (2024-07-01)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)

Developing a diagnostic model for predicting prostate cancer: a retrospective study based on Chinese multicenter clinical data
by: Chang-Ming Wang, et al.
Published: (2024-01-01)

A new parameter to increase the predictive value of multiparametric prostate magnetic resonance imaging for clinically significant prostate cancer in targeted biopsies: lesion density
by: Bahadır Şahin, et al.
Published: (2024-09-01)

Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer
by: Michael A. Bell, et al.
Published: (2018-05-01)

Trends of stratified prostate cancer risk in a single Korean province from 2003 to 2021: A multicenter study conducted using regional training hospital data
by: Young Hwii Ko, et al.
Published: (2023-03-01)

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
by: Sinan Avci, et al.
Published: (2020-04-01)

Diagnostic performance of MRI in detecting prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL: a systematic review and meta-analysis
by: Erjia Guo, et al.
Published: (2024-06-01)

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml
by: Emerson P. Gregorio, et al.
Published: (2007-04-01)

Evaluating whether Prostate Cancer UK’s risk checker is a help or hindrance to prostate-specific antigen testing policy: a mixed-methods study
by: Natalia Norori, et al.
Published: (2024-07-01)

Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis
by: Pieter Logghe, et al.

Serum PSA and cure perspective for prostate cancer in males with nonpalpable tumor
by: Marcos F. Dall'Oglio, et al.
Published: (2005-10-01)

Initial Symptomatic Pituitary Metastasis in a Patient with Prostate Foamy Gland Carcinoma: Tailoring Safe and Effective Therapy
by: Marin Prpić, et al.
Published: (2015-01-01)

Evaluation of concordance between histopathological prognostic findings from prostate needle biopsy samples and serum prostate-specific antigen levels
by: Cengiz Kocak
Published: (2019-03-01)

Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy
by: Marcos F. Dall'oglio, et al.
Published: (2005-06-01)

A Ten-Year Study of Prostate Cancer: A Southern Iranian Experience
by: Mehrzad Lotfi, et al.
Published: (2018-07-01)

Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy
by: In Gab Jeong, et al.
Published: (2013-06-01)